Top-Rated StocksTop-RatedNASDAQ:PCRX Pacira BioSciences (PCRX) Stock Forecast, Price & News $30.85 -0.19 (-0.61%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$30.49▼$31.3050-Day Range$30.85▼$39.4852-Week Range$30.49▼$58.10Volume646,293 shsAverage Volume551,246 shsMarket Capitalization$1.43 billionP/E RatioN/ADividend YieldN/APrice Target$58.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Pacira BioSciences MarketRank™ ForecastAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside88.0% Upside$58.00 Price TargetShort InterestBearish7.58% of Shares Sold ShortDividend StrengthN/ASustainability-1.97Upright™ Environmental ScoreNews Sentiment1.01Based on 9 Articles This WeekInsider TradingSelling Shares$42,773 Sold Last QuarterProj. Earnings Growth39.66%From $2.37 to $3.31 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.87 out of 5 starsMedical Sector56th out of 969 stocksPharmaceutical Preparations Industry14th out of 455 stocks 4.4 Analyst's Opinion Consensus RatingPacira BioSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $58.00, Pacira BioSciences has a forecasted upside of 88.0% from its current price of $30.85.Amount of Analyst CoveragePacira BioSciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.58% of the outstanding shares of Pacira BioSciences have been sold short.Short Interest Ratio / Days to CoverPacira BioSciences has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Pacira BioSciences has recently decreased by 1.40%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPacira BioSciences does not currently pay a dividend.Dividend GrowthPacira BioSciences does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePacira BioSciences has received a 48.44% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Bupivacaine", "Cryotherapy devices", and "Drug delivery devices" products. See details.Environmental SustainabilityThe Environmental Impact score for Pacira BioSciences is -1.97. Previous Next 3.3 News and Social Media Coverage News SentimentPacira BioSciences has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Pacira BioSciences this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added Pacira BioSciences to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pacira BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,773.00 in company stock.Percentage Held by InsidersOnly 6.60% of the stock of Pacira BioSciences is held by insiders.Percentage Held by Institutions99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Pacira BioSciences are expected to grow by 39.66% in the coming year, from $2.37 to $3.31 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pacira BioSciences is -192.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pacira BioSciences is -192.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPacira BioSciences has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Pacira BioSciences (NASDAQ:PCRX) StockPacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.Read More PCRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PCRX Stock News HeadlinesSeptember 27, 2023 | finance.yahoo.comUnveiling Pacira BioSciences (PCRX)'s Value: Is It Really Priced Right? A Comprehensive GuideSeptember 27, 2023 | finance.yahoo.comUnraveling the Future of Pacira BioSciences Inc (PCRX): A Deep Dive into Key MetricsSeptember 28, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 26, 2023 | marketwatch.comPacira BioSciences Chairman, CEO David Stack to RetireSeptember 26, 2023 | msn.comPacira BioSciences CEO David Stack to step downSeptember 26, 2023 | finance.yahoo.comPacira BioSciences Announces Leadership Succession PlanSeptember 6, 2023 | finance.yahoo.comPacira BioSciences Announces Fireside Chat at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 5, 2023 | seekingalpha.comPacira BioSciences: Economic Returns Languish Required Growth RatesSeptember 28, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsAugust 4, 2023 | msn.comNeedham Maintains Pacira BioSciences (PCRX) Buy RecommendationAugust 4, 2023 | msn.comTD Cowen Upgrades Pacira BioSciences (PCRX)August 3, 2023 | markets.businessinsider.com4 Analysts Have This to Say About Pacira BioSciencesAugust 3, 2023 | finance.yahoo.comPacira (PCRX) Q2 Earnings and Sales Miss, '23 View UpdatedAugust 2, 2023 | finance.yahoo.comPacira BioSciences Reports Second Quarter 2023 Financial ResultsAugust 2, 2023 | markets.businessinsider.comPacira Pharmaceuticals earnings preview: what Wall Street is expectingJuly 27, 2023 | finance.yahoo.comPacira to Report Second Quarter 2023 Financial Results on Wednesday August 2, 2023July 13, 2023 | benzinga.comHC Wainwright & Co. Maintains Buy on Pacira BioSciences, Lowers Price Target to $68July 13, 2023 | msn.comHC Wainwright & Co. Maintains Pacira BioSciences (PCRX) Buy RecommendationJuly 13, 2023 | markets.businessinsider.comAnalyst Ratings for Pacira BioSciencesJuly 5, 2023 | finance.yahoo.comPCRX - Pacira BioSciences, Inc.July 2, 2023 | fool.comPacira BioSciences (NASDAQ: PCRX)June 26, 2023 | markets.businessinsider.comBarclays Releases a Buy Rating on Pacira Pharmaceuticals (PCRX)June 2, 2023 | finance.yahoo.comWhy Is Pacira (PCRX) Down 11.8% Since Last Earnings Report?May 31, 2023 | finance.yahoo.comPacira BioSciences to Participate in Fireside Chat at the 2023 Jefferies Healthcare ConferenceMay 18, 2023 | seekingalpha.comPacira Biosciences (PCRX) Investor Presentation - SlideshowMay 15, 2023 | msn.comHere's Why You Should Add Pacira (PCRX) Stock to Your PortfolioMay 10, 2023 | seekingalpha.comPacira BioSciences: Zilretta Story Still Viable, Productivity The Next StepSee More Headlines Receive PCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address PCRX Company Calendar Last Earnings8/02/2023Today9/28/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:PCRX CUSIP69512710 CIK1396814 Webwww.pacira.com Phone(813) 553-6680Fax302-655-5049Employees715Year FoundedN/APrice Target and Rating Average Stock Price Forecast$58.00 High Stock Price Forecast$80.00 Low Stock Price Forecast$50.00 Forecasted Upside/Downside+88.6%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.16) Trailing P/E RatioN/A Forward P/E Ratio12.98 P/E GrowthN/ANet Income$15.91 million Net Margins-0.68% Pretax Margin-0.69% Return on Equity11.56% Return on Assets5.57% Debt Debt-to-Equity Ratio0.66 Current Ratio3.94 Quick Ratio3.10 Sales & Book Value Annual Sales$669.23 million Price / Sales2.13 Cash Flow$3.72 per share Price / Cash Flow8.26 Book Value$16.89 per share Price / Book1.82Miscellaneous Outstanding Shares46,417,000Free Float43,353,000Market Cap$1.43 billion OptionableOptionable Beta0.70 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. David M. Stack (Age 73)Chairman & CEO Comp: $1.54MMr. Charles A. Reinhart III (Age 62)CPA, M.B.A., Chief Financial Officer Comp: $780.58kMr. Daryl Gaugler (Age 61)Chief Operating Officer Comp: $778.77kMs. Kristen Williams J.D. (Age 49)Chief Admin. Officer & Sec. Comp: $799.63kMr. Anthony Molloy III (Age 49)Esq., Chief Legal & Compliance Officer Comp: $581.41kMs. Lauren Bullaro Riker (Age 44)Principal Accounting Officer & VP of Fin. Susan MescoHead of Investor RelationsMr. Richard KahrVP of HRDr. Roy Winston M.D. (Age 62)Chief Medical Officer & Orthopedic Franchise Mr. Dennis McLoughlin (Age 57)Chief Customer Officer More ExecutivesKey CompetitorsSupernus PharmaceuticalsNASDAQ:SUPNCorcept TherapeuticsNASDAQ:CORTPerrigoNYSE:PRGOIDEAYA BiosciencesNASDAQ:IDYACrinetics PharmaceuticalsNASDAQ:CRNXView All CompetitorsInsiders & InstitutionsVirginia Retirement Systems ET ALBought 7,400 shares on 8/22/2023Ownership: 0.016%California State Teachers Retirement SystemSold 1,434 shares on 8/21/2023Ownership: 0.120%Teachers Retirement System of The State of KentuckyBought 805 shares on 8/21/2023Ownership: 0.032%Segall Bryant & Hamill LLCBought 397 shares on 8/15/2023Ownership: 0.203%Natixis Advisors L.P.Bought 1,638 shares on 8/15/2023Ownership: 0.026%View All Insider TransactionsView All Institutional Transactions PCRX Stock - Frequently Asked Questions Should I buy or sell Pacira BioSciences stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PCRX shares. View PCRX analyst ratings or view top-rated stocks. What is Pacira BioSciences' stock price forecast for 2023? 9 Wall Street research analysts have issued 12 month target prices for Pacira BioSciences' shares. Their PCRX share price forecasts range from $50.00 to $80.00. On average, they expect the company's share price to reach $58.00 in the next twelve months. This suggests a possible upside of 88.6% from the stock's current price. View analysts price targets for PCRX or view top-rated stocks among Wall Street analysts. How have PCRX shares performed in 2023? Pacira BioSciences' stock was trading at $38.61 on January 1st, 2023. Since then, PCRX shares have decreased by 20.3% and is now trading at $30.76. View the best growth stocks for 2023 here. When is Pacira BioSciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our PCRX earnings forecast. How were Pacira BioSciences' earnings last quarter? Pacira BioSciences, Inc. (NASDAQ:PCRX) released its earnings results on Wednesday, August, 2nd. The company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.59 by $0.02. The firm earned $169.47 million during the quarter, compared to the consensus estimate of $175.64 million. Pacira BioSciences had a negative net margin of 0.68% and a positive trailing twelve-month return on equity of 11.56%. What ETFs hold Pacira BioSciences' stock? ETFs with the largest weight of Pacira BioSciences (NASDAQ:PCRX) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), SPDR S&P Pharmaceuticals ETF (XPH), Invesco S&P SmallCap Health Care ETF (PSCH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE). What is Dave Stack's approval rating as Pacira BioSciences' CEO? 54 employees have rated Pacira BioSciences Chief Executive Officer Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among the company's employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Pacira BioSciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA). What is Pacira BioSciences' stock symbol? Pacira BioSciences trades on the NASDAQ under the ticker symbol "PCRX." Who are Pacira BioSciences' major shareholders? Pacira BioSciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Frontier Capital Management Co. LLC (3.63%), Baillie Gifford & Co. (3.61%), Renaissance Technologies LLC (3.39%), Stephens Investment Management Group LLC (2.88%), Clearbridge Investments LLC (2.49%) and Dimensional Fund Advisors LP (2.42%). Insiders that own company stock include Andreas Wicki, Anthony Molloy, Charles A Reinhart III, Charles Anthony Laranjeira, Daryl Gaugler, David M Stack, David M Stack, Donald C Manning, Gary W Pace, John P Phd Longenecker, Jonathan Slonin, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Max Reinhardt, Paul J Hastings and Roy Winston. View institutional ownership trends. How do I buy shares of Pacira BioSciences? Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Pacira BioSciences' stock price today? One share of PCRX stock can currently be purchased for approximately $30.76. How much money does Pacira BioSciences make? Pacira BioSciences (NASDAQ:PCRX) has a market capitalization of $1.43 billion and generates $669.23 million in revenue each year. The company earns $15.91 million in net income (profit) each year or ($0.16) on an earnings per share basis. How many employees does Pacira BioSciences have? The company employs 715 workers across the globe. How can I contact Pacira BioSciences? Pacira BioSciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The official website for the company is www.pacira.com. The company can be reached via phone at (813) 553-6680, via email at susan.mesco@pacira.com, or via fax at 302-655-5049. This page (NASDAQ:PCRX) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.